Market Leadership Alphapharm is the leading supplier of generic medicines within Australia, serving the Pharmaceutical Benefits Scheme which indicates strong government partnerships and reliable revenue streams that could be expanded to other markets or sectors.

Global Export Presence With products exported to more than 50 countries including Europe and the US, Alphapharm offers opportunities to collaborate on international distribution channels and regulatory entry strategies, enhancing global supply chain capabilities.

Diverse Product Portfolio Ownership of a broad, high-quality product range supported by a robust pipeline and a controlling interest in a major active pharmaceutical ingredient manufacturer presents opportunities for tailored product development and supply chain optimization.

Financial Growth Potential Generating between $25 million and $50 million in revenue within the generics sector highlights potential for scaling operations, especially through partnerships that can broaden product offerings or improve manufacturing efficiencies.

Industry Position As part of Mylan Inc. and aligned with a leading global pharmaceutical group, Alphapharm’s positioning offers avenues for strategic collaborations, especially in respiratory and allergy therapies, and enhances credibility in both domestic and international markets.